专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU2001274459B2 Pharmaceutical compositions comprising cannabidiol derivatives 未知
公开(公告)号：AU2001274459B2
公开(公告)日：2005-07-07
申请号：AU2001274459
申请日：2001-06-12
申请人： YISSUM RES DEV CO
发明人： GALLILY RUTH , BREUER AVIVA , HANUS LUMIR , FRIDE ESTER , TCHILIBON SUSANA , MECHOULAM RAPHAEL
IPC分类号： A61K9/08 , A61K9/10 , A61K9/14 , A61K9/20 , A61K9/48 , A61K31/05 , A61K31/065 , A61K31/192 , A61K31/222 , A61K47/08 , A61K47/10 , A61K47/24 , A61P25/00 , A61P25/08 , A61P25/18 , A61P25/22 , A61P29/00 , A61P35/00 , A61P43/00 , C07C37/055 , C07C39/23 , C07C43/23 , C07C51/367 , C07C59/54 , C07C59/72 , C07C62/32 , C07C69/017 , A61K031/192 , A61P029/00 , A61P025/00 , A61P035/00 , A61K041/00 , C07C051/29 , C07C059/72 , C07C059/54 , C07C039/23 , C07C043/178 , C07C043/23 , A61K009/107 , A61K031/075 , A61K031/085 , A61K031/05
摘要： The present invention relates to cannabidiol derivatives and to pharmaceutical compositions comprising cannabidiol derivatives being antiinflammatory agents having analgesic, antianxiety, anticonvulsive, neuroprotective, antipsychotic and anticancer activity. The present invention also relates to a process for the preparation of cannabidiol derivatives. It also relates to the use of cannabidiol derivatives and of pharmaceutical compositions comprising same in the preparation of a medicament, in a method of the treatment of human beings with cannabidiol derivatives or with a pharmaceutical preparations comprising same.

2. 发明专利

AU2001235972B2 Clear aqueous anaesthetic composition 未知
公开(公告)号：AU2001235972B2
公开(公告)日：2005-07-21
申请号：AU2001235972
申请日：2000-12-14
申请人： BHARAT SERUMS & VACCINES LTD
发明人： KOCHAREKAR SHILPA , RIVANKAR SANGEETA , PAI SRIKANTH
IPC分类号： A61K9/08 , A61K9/00 , A61K31/05 , A61K47/02 , A61K47/04 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/20 , A61K47/22 , A61K47/26 , A61K47/34 , A61K47/40 , A61K47/48 , A61P23/00 , A61K031/05 , A61K047/48
摘要： Sterile pharmaceutical stable autoclaved clear aqueous compositions of propofol (2,6-Diisopropyl phenol) suitable for parenteral administration are described. The compositions essentially consist of a complex of propofol with 2-hydroxypropyl-beta-cyclodextrin in a weight ratio of 1:30-1:60. This complex of propofol with 2-hydroxypropyl-beta-cyclodextrin produces a clear aqueous composition that is stable to autoclaving. The composition is effective as an anaesthetic agent. The process of making these synergistic compositions has been described.

3. 发明申请

US20040266888A1 Composition for treatment of infections of humans and animals 审中-公开
标题翻译：用于治疗人和动物感染的组合物
公开(公告)号：US20040266888A1
公开(公告)日：2004-12-30
申请号：US10715886
申请日：2003-11-17
申请人： Van Beek Global/Ninkov L.L.C.
发明人： Dusan Ninkov
IPC分类号： A61K031/05
CPC分类号： B01F15/065 , A61K31/05 , A61K36/23 , A61K36/53 , A61K36/534 , A61K36/61 , A61K36/67 , A61K36/75 , A61K36/85 , B01F7/22 , B01F2015/062 , B01F2215/0472 , B01F2215/0477 , B01F2215/0481 , Y02A50/473 , A61K2300/00
摘要： This disclosure provides pharmaceutical compositions which include oil extract from plants from the Labiatae family. In particular, the compositions can be formulated by combining extracts of essential oils from plants of the Labiatae family with an organic acid or a Group I salt. It is believed that the antimicrobial activity of the pharmaceutical composition is due to the presence of organic phenols, such as isopropyl-o-cresol, in the oil extract from the plants.
摘要翻译：本公开提供了药物组合物，其包括来自Labiatae家族的植物的油提取物。特别地，组合物可以通过将Labiatae家族植物的精油提取物与有机酸或I类盐组合来配制。据信药物组合物的抗微生物活性是由植物油提取物中有机酚如异丙基邻甲酚的存在引起的。

4. 发明申请

US20040192763A1 NMDA NR2B antagonists for treatment 审中-公开
标题翻译： NMDA NR2B拮抗剂治疗
公开(公告)号：US20040192763A1
公开(公告)日：2004-09-30
申请号：US10821526
申请日：2004-04-09
申请人： Pfizer, Inc. , Pfizer Products, Inc.
发明人： Bertrand L. Chenard , Frank S. Menniti , Mario D. Saltarelli
IPC分类号： A61K031/353 , A61K031/05
CPC分类号： A61K31/46 , A61K31/00 , A61K31/4015 , A61K31/445 , A61K31/452 , A61K31/453
摘要： The invention provides new methods for treating certain disorders resulting from neurodegeneration and for treating depression which comprise administration of NR2B subunit selective NMDA antagonists. The disorders that can be treating by the invention include hearing loss, vision loss, neurodegeneration caused by epileptic seizures, neurotoxin poisoning, Restless Leg Syndrome, multi-system atrophy, non-vascular headache, and depression.
摘要翻译：本发明提供用于治疗由神经变性引起的某些疾病和治疗包括施用NR2B亚基选择性NMDA拮抗剂的抑郁症的新方法。可以通过本发明治疗的疾病包括听力损失，视力丧失，由癫痫发作引起的神经变性，神经毒素中毒，不宁腿综合征，多系统萎缩，非血管性头痛和抑郁症。

5. 发明申请

US20040171691A1 Propofol with cysteine 审中-公开
标题翻译：丙泊酚与半胱氨酸
公开(公告)号：US20040171691A1
公开(公告)日：2004-09-02
申请号：US10695291
申请日：2003-10-28
申请人： Transform Pharmaceuticals, Inc.
发明人： Hua Tang , Hongming Chen , Orn Almarsson
IPC分类号： A61K031/198 , A61K031/05
CPC分类号： A61K9/0019 , A61K31/05 , A61K31/198 , A61K47/12 , A61K47/14 , A61K47/183 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions comprising 2,6-diisopropylphenol (propofol). Compositions of the present invention comprise aqueous and non-aqueous compositions of propofol and cysteine or a salt thereof. The propofol containing compositions are preferably sterile and are parenterally administered to any animal, including humans.
摘要翻译：本发明涉及包含2,6-二异丙基苯酚（丙泊酚）的药物组合物。本发明的组合物包含异丙酚和半胱氨酸的水性和非水性组合物或其盐。含有异丙酚的组合物优选是无菌的，并且肠胃外给予任何动物，包括人。

6. 发明申请

US20040132830A1 Triphenylmethane kinesin inhibitors 审中-公开
标题翻译：三苯甲烷驱动蛋白抑制剂
公开(公告)号：US20040132830A1
公开(公告)日：2004-07-08
申请号：US10466760
申请日：2004-02-17
发明人： Jeffrey T Finer , John C Chabala , Evan Lewis
IPC分类号： A61K031/05
CPC分类号： C07C317/22 , A61K31/05 , A61K31/085 , A61K31/10 , A61K31/136 , A61K31/192 , A61K49/0004 , C07C39/15 , C07C43/225 , C07C43/23 , C07C205/60 , C07C211/50 , C07C215/74 , C07C229/52 , C07C323/18
摘要： Triphenylmethane derivatives of the formula (I) are disclosed. The compounds are inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases, such as cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation
摘要翻译：公开了式（I）的三苯基甲烷衍生物。这些化合物是有丝分裂驱动蛋白KSP的抑制剂，可用于治疗细胞增殖性疾病，如癌症，增生，再狭窄，心脏肥大，免疫疾病和炎症

7. 发明申请

US20040110847A1 Compounds extracted from Sap of Rhus succedanea 审中-公开
标题翻译：从苦参皂甙提取的化合物
公开(公告)号：US20040110847A1
公开(公告)日：2004-06-10
申请号：US10166918
申请日：2002-06-11
发明人： Pei-Lin Wu , Shwu-Bin Lin , Robin Yih-Yuan Chiou
IPC分类号： A61K031/05 , C07C039/08
CPC分类号： C07C37/004 , C07C39/19
摘要： The present invention relates to new antioxidative and cytotoxic hydroquinone compounds 10null(Z),13null(E),15null(E)-heptadecatrienylhydroquinone (1) and 10null(Z),13null(E)-heptadecadienylhydroquinone (2) that were mainly isolated from an ethanol extract of the sap of Rhus succedanea. The structures of these compounds were determined by spectral analyses and showed potent antioxidative activity and cytotoxicity against human cancer cells. This invention also includes anti-tumor pharmaceutical composition of the hydroquinone compounds.
摘要翻译：本发明涉及新的抗氧化和细胞毒性氢醌化合物10'（Z），13'（E），15'（E） - 十五碳三烯基氢醌（1）和10'（Z），13'（E） - 十五碳二烯基氢醌（2）主要从苦参皂甙的乙醇提取物中分离出来。通过光谱分析测定这些化合物的结构，并显示出对人类癌细胞的有效的抗氧化活性和细胞毒性。本发明还包括氢醌化合物的抗肿瘤药物组合物。

8. 发明申请

US20040087666A1 Calixarene-based guest-host assemblies for guest storage and transfer 有权
标题翻译：用于客人存储和转移的基于Calixarene的客座主机组件
公开(公告)号：US20040087666A1
公开(公告)日：2004-05-06
申请号：US10286179
申请日：2002-10-31
发明人： Jerry L. Atwood , Leonard J. Barbour , Agoston Jerga
IPC分类号： A61K031/05 , C07C039/16
CPC分类号： B82Y5/00 , A61K47/6949 , C07C39/17
摘要： A guest host assembly comprising a host assembly formed of calixarene molecules and a guest component located within the host assembly. A crystallographic assembly of layers of the calixarene molecules and stacked along the crystallographic c axis of the assembly in a repeating configuration associated together predominantly by van der Waal forces. The guest component is transferable through the host assembly in a direction normal to the stacked layers. The calixarene molecules are configured in bilayers of adjacent layers along the c axis. The bilayers are shifted along the a or b axis so the assembly, relative to a corresponding assembly of the calixarene molecules without the inclusion of the guest component is shifted. The calixarene are calix(N)arenes in which N is an integer within the range of 4-8. The calixarene molecules are distally substituted with a substituent such as methyl, ethyl, propyl, butyl amyl or phenyl groups.
摘要翻译：包括由杯芳烃分子形成的主体组件和位于所述主机组件内的客体组件的客舱主机组件。杯状分子的层的晶体组合并且以组装的晶体c轴重叠，主要由范德华力联合在一起。客体部件可以沿垂直于层叠层的方向通过主机组件传送。杯芳烃分子沿着c轴配置在相邻层的双层中。双层沿着a或b轴移动，因此相对于杯芳烃分子的相应组件而不包括客体组分的组件发生偏移。杯芳烃是杯（N）芳烃，其中N是4-8范围内的整数。杯芳烃分子被甲基，乙基，丙基，丁基戊基或苯基等取代基远端取代。

9. 发明申请

US20040067919A1 Injectable 2, 6-diisopropylphenol-containing anesthetic composition and methods 审中-公开
标题翻译：注射2,6-二异丙基苯酚的麻醉剂组合物和方法
公开(公告)号：US20040067919A1
公开(公告)日：2004-04-08
申请号：US10615763
申请日：2003-07-08
申请人： Centurion Inc.
发明人： Ung-Kil Jee
IPC分类号： A61K031/05 , A61K031/56
CPC分类号： A61K9/1075 , A61K31/05 , A61K31/56
摘要： An injectable anesthetic composition in a microemulsion phase is disclosed. The composition contains 2,6-diisopropylphenol as the active ingredient, together with polyethylene glycol 660 hydroxystearate, tetrahydrofurfuryl alcohol polyethyleneglycol ether, and an aqueous medium. Methods of making and using the injectable anesthetic composition are also disclosed.
摘要翻译：公开了一种微乳液相中的可注射麻醉组合物。该组合物含有2,6-二异丙基苯酚作为活性成分，以及聚乙二醇660羟基硬脂酸酯，四氢糠醇聚乙二醇醚和水性介质。还公开了制备和使用可注射麻醉剂组合物的方法。

10. 发明申请

US20040033480A1 Use of resveratrol to regulate expression of apolipoprotein A1 审中-公开
标题翻译：使用白藜芦醇调节载脂蛋白A1的表达
公开(公告)号：US20040033480A1
公开(公告)日：2004-02-19
申请号：US10222013
申请日：2002-08-15
发明人： Norman C.W. Wong
IPC分类号： C12Q001/00 , C12Q001/68 , A61K031/05
CPC分类号： G01N33/92 , A61K31/05 , C12Q1/6883 , C12Q1/6897 , C12Q2600/136 , C12Q2600/158 , G01N2500/10 , G01N2800/044
摘要： Described are new methods for promoting the expression of apolipoprotein A1 (APO A1) for increasing levels of HDL, and assays for screening and identifying compounds for regulating expression of the APO A1 protein.
摘要翻译：描述了促进载脂蛋白A1（APO A1）表达以增加HDL水平的新方法，以及用于筛选和鉴定调节APO A1蛋白表达的化合物的测定法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式